The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Like you, I'm baffled, and it seems just a matter of time before a rerate. And I had planned to double my investment here this morning, however the RNS director sells just put me off putting more in.
Why on earth is a director selling like that, at this price, and just 10 days before an ex div date?
What am I missing???
Just to reiterate:
RNS 17/01 : "tumour biopsies . . . . . . confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue". "This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels".
- Note the use of the word ACTIVE chemotherapy, and as we all know "at therapeutic levels"
One of the trial conditions: "Patients in Phase Ia will receive escalating doses of AVA6000 . . . . . . until disease progression", . . . . etc.
- So, AVA6000 must have stopped cancer cell reproduction/spread for 19 of the patients, else their treatment would have stopped. This is unequivocal - AVA6000 had to stop cancer progression in order for the trial to continue.
IT WORKS!
Also in RNS 17/01:
"The data being generated in the ALS-6000-101 study are providing detailed insights into the pre|CISIONTM platform which add significant value to the technology"
This is a bold statement: "Data . . .. providing DETAILED insights . . . . which ADD SIGNIFICANT VALUE to the technology". Not might add, could add, has the potential to add value - but ADDS value as a statement of fact. They cannot make a statement like this if it were not true.
I know people can read, but this debate is being undermined by people with disruptive agendas, and anybody concerned about the negative comments or price retrace over the last couple of days - should just ignore all of the noise, re-read the 17/01 RNS - look at the trial conditions, and you will be reassured that AVACTA have a valuable chemotherapy treatment, with no meaningful side effects, which works!
Please just use your green boxes and stop engaging with those who have an agenda or add no value.
I got fed up with this board until I binned:
- derampers : wynbore etc. who always have a negative agenda
- rampers who add no value/insight
- traders who praise the stock one week and slate it the next
and its a much better board for me now.
But people that keep saying don't engage with the FUD'ers whilst continually engaging with the FUD'ers is not helping!
Thanks. GLA.
Buys and sells almost the same, and SP dropping on very little volume (£30k).
Not great. But as mentioned, we just need some positive news to turn this around - and in future, some more reliable timeline aspirations would help.
GLA
Yes very good results. And in a period where you might expect them not to be.
I'm not sure what resistance you are referring to - the SP has steadily climbed 20% over the past 5 months, and still looks good value.
Avacta can't yet use the phrase "chemo without side effects" because they are still increasing the dosage, and its possible that some side effects might emerge.
But they have told us that dox is at theraputic levels in the tumour at low dosage and at "much" greater levels than in healthy tissues. From this, I think we can conclude that the worst case scenario is effective chemo with minimal side effects.
And chemo without side effects remains a real possibility.
Phase 1a has just been extended by 6 months (Avacta time, so probably much longer), and traders are therefore selling and investors are buying. Hence the muted reaction to brilliant news.
But I don't care, Avacta have always had too large a Private Investor contingent and not enough Institutional Investors and todays RNS will change that. Avacta also know it, with the Science Day already booked in.
II's will happily plough into Avacta now at levels well above today's SP . . . . they just move more slowly than PI's
Sit back and enjoy the ride.
Ronny, we don't know, and phase 1a is presumably continuing to enhance the therapeutic affect.
BUT, it really doesn't matter much, as the important point is that we know the chemo is going into the tumour at a "MUCH" higher rate, and therefore increasing the dose will ultimately provide chemo treatment with MUCH reduced (or no) side affects.
Up 20% today on just £144,000 of buys is crazy price action.
I was disappointed not to see more buying action on such a big rise, but on the plus side, it looks like there are a lot of sticky hands that expect this to do a lot better in the long run.
GLA